DEA sweeping new laws under the rug?

Matt White

Days ago, the DEA took yet another stab at marijuana by amending its already bizarre classification of pot as a Schedule I drug. Thumbs down to yet another bureaucratic overreach. Now, all extracts, including cannabidiol (CBD), will be listed right up there with heroin as a “drug with no medical use.” No medical use? Tell that to the thousands of epilepsy sufferers, who are mercifully enjoying relief from intractable epilepsy and polymorphic seizures. No, I’m not some pot head, and, but yes, (full disclosure) I do feel that responsible recreational consumption of the drug should be legalized—but more importantly the efficacy of the plants internal compounds with regard to it’ medicinal value absolute should not be fodder for DEA classification as an infamous Schedule 1. Interesting, since the DEA can only carry out the law, not create it. But even as the DEA is now considering CBD oil to be a federally illegal Schedule I drug (let’s face it, they always have), there are temporary safeguards in place that protect patients in many states from federal prosecution over possession of the oil—such as the Rohrabacher-Farr amendment. This 2014 amendment to a Congressional appropriations bill prohibits the Justice Department from spending funds to interfere with the implementation of state medical cannabis laws; upheld as recently as August in Federal 9th U.S. Circuit Court in the face of a challenge brought by federal prosecutors.